Methods used in economic evaluations of chronic kidney disease testing - A systematic review

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Sutton, Andrew J ^a   Breheny, Katie ^a   Deeks, Jon ^a   Khunti, Kamlesh ^b   Sharpe, Claire ^c   Ottridge, Ryan S ^a   Stevens, Paul E ^d   Cockwell, Paul ^a,f   Kalra, Philp A ^e   Lamb, Edmund J ^d   Brettell, E A ^a   Dalton, R N ^g   Barratt, J ^h   Higgins, T ⁱ   Loud, F ^j   Sitch, A J ^a   Taal, M W ^k  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^e SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

ⁱ UNIVERSITY OF KENT   (United Kingdom)

^j British Kidney Patient Association   (United Kingdom)

^k ROYAL DERBY HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTICAL PARAMETERS; ANXIETY; CHRONIC KIDNEY DISEASE; COST; DIAGNOSTIC ACCURACY; ECONOMIC EVALUATION; FALSE POSITIVE RESULT; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HUMAN; KIDNEY FUNCTION TEST; LIFE YEARS GAINED; PATIENT IDENTIFICATION; PATIENT MONITORING; PROTEINURIA; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SCREENING TEST; SENSITIVITY ANALYSIS; SOCIETAL COST; SYSTEMATIC REVIEW; URINE ALBUMIN TO CREATININE RATIO; URINE PROTEIN TO CREATININE RATIO; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; FEMALE; MALE; META ANALYSIS; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY; STANDARDS;

COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; MALE; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS;

EID: 84949035858     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140063     Document Type: Review

References (45)

1. Arora P, Vasa P, Brenner D, Iglar K, McFarlane P, Morrison H, Badawi A (2013) Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. CMAJ 185: E417-E423. cmaj.120833 [pii];doi: 10.1503/cmaj.120833 PMID: 23649413
2. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, et al. (2012) Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 379: 815-822. S0140-6736(12)60033-6 [pii];doi: 10.1016/S0140-6736(12)60033-6 PMID: 22386035
3. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. (2009) Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 13: 621-630. doi: 10.1007/s10157-009-0199-x PMID: 19513802
4. Otero A, de FA, Gayoso P, Garcia F (2010) Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrologia 30: 78-86. doi: 10.3265/Nefrologia.pre2009.Dic.5732 PMID: 20038967
5. Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, et al. (2006) International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 17: 2275-2284. ASN.2005121273 [pii];doi: 10.1681/ASN.2005121273 PMID: 16790511
6. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. (2007) Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047. 298/17/2038 [pii];doi: 10.1001/jama.298.17. 2038 PMID: 17986697
7. Radhakrishnan J, Remuzzi G, Saran R, Williams DE, Rios-Burrows N, Powe N, et al. (2014) Taming the chronic kidney disease epidemic: a global view of surveillance efforts. Kidney Int 86: 246-250. ki2014190 [pii];doi: 10.1038/ki.2014.190 PMID: 24897034
8. Fraser SD, Roderick PJ, Aitken G, Roth M, Mindell JS, Moon G, et al. (2013) Chronic kidney disease, albuminuria and socioeconomic status in the Health Surveys for England 2009 and 2010. J Public Health (Oxf). fdt117 [pii];doi: 10.1093/pubmed/fdt117
9. Stevens PE, Levin A (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158: 825-830. 1691737 [pii];doi: 10.7326/0003-4819-158-11-201306040-00007 PMID: 23732715
10. Lamb EJ, Brettell EA, Cockwell P, Dalton N, Deeks JJ, Harris K, et al. (2014) The eGFR-C study: accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease - prospective longitudinal study in a multiethnic population. BMC Nephrol 15:13. 1471-2369-15-13 [pii];doi: 10.1186/1471-2369-15-13 PMID: 24423077
11. Carville S, Wonderling D, Stevens P (2014) Early identification and management of chronic kidney disease in adults: summary of updated NICE guidance. BMJ 349: g4507. doi: 10.1136/bmj.g4507 PMID: 25059691
12. Farmer AJ, Stevens R, Hirst J, Lung T, Oke J, Clarke P, et al. (2014) Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness. Health Technol Assess 18: 1-128. doi: 10.3310/hta18140
13. Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. (2011) Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 80: 93-104. ki2010531 [pii];doi: 10.1038/ki.2010.531 PMID: 21289597
14. Collins RE, Lopez LM, Marteau TM (2011) Emotional impact of screening: a systematic review and meta-analysis. BMC Public Health 11: 603. 1471-2458-11-603 [pii];doi: 10.1186/1471-2458-11-603 PMID: 21798046
15. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S (2007) Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 335: 486. bmj.39303.723449.55 [pii];doi: 10.1136/bmj.39303. 723449.55 PMID: 17761995
16. Skinner TC, Davies MJ, Farooqi AM, Jarvis J, Tringham JR, Khunti K (2005) Diabetes screening anxiety and beliefs. Diabet Med 22: 1497-1502. DME1680 [pii];doi: 10.1111/j.1464-5491.2005.01680.x PMID: 16241913
17. Moynihan R, Doust J, Henry D (2012) Preventing overdiagnosis: how to stop harming the healthy. BMJ 344: e3502. doi: 10.1136/bmj.e3502 PMID: 22645185
18. TaalMW(2012) Screening for chronic kidney disease: preventing harm or harming the healthy? PLoS Med 9: e1001345. doi: 10.1371/journal.pmed.1001345; PMEDICINE-D-12-02978 [pii]. PMID: 23185137
19. Levin A, Stevens PE (2011) Early detection of CKD: the benefits, limitations and effects on prognosis. Nat Rev Nephrol 7: 446-457. nrneph.2011.86 [pii];doi: 10.1038/nrneph.2011.86 PMID: 21712852
20. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press.
21. Drummond MF, Jefferson TO (1996) Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 313: 275-283. PMID: 8704542
22. Gonzalez-Perez JG (2002) Developing a scoring system to quality assess economic evaluations. Eur J Health Econ 3: 131-136. doi: 10.1007/s10198-002-0100-2 PMID: 15609137
23. Hoerger TJ, Wittenborn JS, Segel JE, Burrows NR, Imai K, Eggers P, et al. (2010) A health policy model of CKD:1. Model construction, assumptions, and validation of health consequences. Am J Kidney Dis 55: 452-462. S0272-6386(09)01597-2 [pii];doi: 10.1053/j.ajkd.2009.11.016 PMID: 20116911
24. Hoerger TJ, Wittenborn JS, Segel JE, Burrows NR, Imai K, Eggers P, et al. (2010) A health policy model of CKD:2. The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis 55: 463-473. S0272-6386(09)01598-4 [pii];doi: 10.1053/j.ajkd.2009.11.017 PMID: 20116910
25. Hoerger TJ, Wittenborn JS, Zhuo X, Pavkov ME, Burrows NR, Eggers P, et al. (2012) Cost-effectiveness of screening for microalbuminuria among African Americans. J Am Soc Nephrol 23: 2035-2041. 23/12/2035 [pii];doi: 10.1681/ASN.2012040347 PMID: 23204444
26. Kessler R, Keusch G, Szucs TD, Wittenborn JS, Hoerger TJ, Brugger U, et al. (2012) Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland. Swiss Med Wkly 142: w13508. doi: 10.4414/smw.2012.13508; smw-13508 [pii]. PMID: 22307760
27. Boersma C, Gansevoort RT, Pechlivanoglou P, Visser ST, van Toly FF, de Jong-van den Berg LT, et al. (2010) Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands. Clin Ther 32: 1103-1121. S0149-2918(10)00204-3 [pii];doi: 10.1016/j.clinthera.2010.06. 013 PMID: 20637965
28. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR (2003) Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 290: 3101-3114. doi: 10.1001/jama.290.23.3101; 290/23/3101 [pii]. PMID: 14679273
29. den Hartog JR, Reese PP, Cizman B, Feldman HI (2009) The costs and benefits of automatic estimated glomerular filtration rate reporting. Clin J Am Soc Nephrol 4: 419-427. CJN.04080808 [pii];doi: 10.2215/CJN.04080808 PMID: 19176794
30. Kondo M, Yamagata K, Hoshi SL, Saito C, Asahi K, Moriyama T, et al. (2012) Cost-effectiveness of chronic kidney disease mass screening test in Japan. Clin Exp Nephrol 16: 279-291. doi: 10.1007/s10157-011-0567-1 PMID: 22167460
31. Manns B, Hemmelgarn B, Tonelli M, Au F, Chiasson TC, Dong J, et al. (2010) Population based screening for chronic kidney disease: cost effectiveness study. BMJ 341: c5869. doi: 10.1136/bmj.c5869 PMID: 21059726
32. Sekhar DL, Wang L, Hollenbeak CS, Widome MD, Paul IM (2010) A cost-effectiveness analysis of screening urine dipsticks in well-child care. Pediatrics 125: 660-663. peds.2009-1980 [pii];doi:10. 1542/peds.2009-1980 PMID: 20231188
33. Adarkwah CC, Gandjour A, Akkerman M, Evers SM (2011) Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands - a Markov model. PLoS One 6: e26139. doi: 10.1371/journal.pone.0026139; PONE-D-11-10114 [pii]. PMID: 22022539
34. Kiberd BA, Jindal KK (1995) Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ 311: 1595-1599. PMID: 8555801
35. Siegel JE, Krolewski AS, Warram JH, Weinstein MC (1992) Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol 3: S111-S119. PMID: 1457753
36. Srisubat A, Sriratanaban J, Ngamkiatphaisan S, Tungsanga K (2014) Cost-effectiveness of annual microalbuminuria screening in Thai diabetics. Asian Biomedicine 8: 371-379.
37. Le Floch JP, Charles MA, Philippon C, Perlemuter L (1994) Cost-effectiveness of screening for microalbuminuria using immunochemical dipstick tests or laboratory assays in diabetic patients. Diabet Med 11: 349-356. PMID: 8088106
38. Adarkwah CC, Gandjour A (2010) Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany. Int J Technol Assess Health Care 26: 62-70. S0266462309990584 [pii];doi: 10.1017/S0266462309990584 PMID: 20059782
39. Kiberd BA, Jindal KK (1998) Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation. Am J Kidney Dis 31: 49-54. S0272638698000079 [pii]. PMID: 9428451
40. Kiberd BA, Jindal KK (1999) Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure? Mayo Clin Proc 74: 559-564. S0025-6196(11)64130-X [pii];doi: 10.4065/74.6.559 PMID: 10377929
41. Golan L, Birkmeyer JD, Welch HG (1999) The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 131: 660-667. 199911020-00005 [pii]. PMID: 10577328
42. Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, et al. (2008) A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant 23: 1216-1223. gfn082 [pii];doi: 10.1093/ndt/gfn082 PMID: 18359872
43. Howard K, White S, Salkeld G, McDonald S, Craig JC, Chadban S, et al. (2010) Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis. Value Health 13: 196-208. S1098-3015(10)60363-4 [pii];doi: 10.1111/j.1524-4733.2009. 00668.x PMID: 19878493
44. Newman TB, Kohn MA (2009) Evidence-Based Medicine. New York: Cambridge University Press.
45. Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, et al. (2014) Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis 63: 789-797. S0272-6386 (14)00024-9 [pii];doi: 10.1053/j.ajkd.2013.12.012 PMID: 24529536